WHO Raises Warning Over Severe Lack of Obesity Jabs

Fewer than a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, warns the WHO as it releases its inaugural recommendations on the drugs.

With over a billion people worldwide currently living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.

Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.

"Our latest guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the injections that can assist patients in reducing substantial weight, explains the body.

GLP-1 Therapy Supply Crisis

Despite the present best projected case, the production of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, per the health organization.

The guideline urges nations and manufacturers to expand availability, through approaches including licensing agreements.

The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.

The Way Weight-Loss Injections Work

These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so people eat less.

People typically see weight reduction in the initial weeks of starting on the weekly injections.

Studies points to people may see weight return within a year of stopping the treatment, as their normal food cravings return.

To be above a healthy weight raises your likelihood for developing diseases, including diabetes, cardiovascular issues, stroke, and specific cancers.

Excess weight concerns people in every country and was linked to millions of deaths worldwide in 2024, according to the health agency.